Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (HRMY) Financial Performance & Income Statement Overview
Analyze Harmony Biosciences Holdings, Inc. (HRMY) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Harmony Biosciences Holdings, Inc. (HRMY) Income Statement & Financial Overview
Review Harmony Biosciences Holdings, Inc. HRMY income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $200.49M | $184.73M | $201.27M | $186.04M |
| Cost of Revenue | $38.15M | $31.99M | $54.41M | $42.78M |
| Gross Profit | $162.34M | $152.74M | $146.86M | $143.26M |
| Gross Profit Ratio | $0.81 | $0.83 | $0.73 | $0.77 |
| R&D Expenses | $50.16M | $34.54M | $34.67M | $25.39M |
| SG&A Expenses | $64.00M | $61.95M | $56.47M | $56.16M |
| Operating Expenses | $114.16M | $96.49M | $91.13M | $81.55M |
| Total Costs & Expenses | $152.31M | $128.49M | $145.54M | $124.33M |
| Interest Income | $5.30M | $5.04M | $4.48M | $4.93M |
| Interest Expense | -$3.65M | -$3.84M | $4.21M | $4.35M |
| Depreciation & Amortization | $0.00 | $5.97M | $5.97M | $5.97M |
| EBITDA | $48.18M | $66.98M | $66.33M | $72.49M |
| EBITDA Ratio | $0.24 | $0.36 | $0.33 | $0.39 |
| Operating Income | $48.18M | $56.24M | $55.73M | $61.71M |
| Operating Income Ratio | $0.24 | $0.30 | $0.28 | $0.33 |
| Other Income/Expenses (Net) | $1.46M | $932000.00 | $428000.00 | $460000.00 |
| Income Before Tax | $49.64M | $57.18M | $56.16M | $62.17M |
| Income Before Tax Ratio | $0.25 | $0.31 | $0.28 | $0.33 |
| Income Tax Expense | -$9.86M | -$11.62M | $6.68M | $16.08M |
| Net Income | $39.78M | $45.56M | $49.48M | $46.09M |
| Net Income Ratio | $0.20 | $0.25 | $0.25 | $0.25 |
| EPS | $0.69 | $0.79 | $0.87 | $0.81 |
| Diluted EPS | $0.68 | $0.78 | $0.85 | $0.79 |
| Weighted Avg Shares Outstanding | $57.47M | $57.31M | $57.10M | $56.87M |
| Weighted Avg Shares Outstanding (Diluted) | $58.43M | $58.52M | $58.22M | $58.10M |
Over the last four quarters, Harmony Biosciences Holdings, Inc. achieved steady financial progress, growing revenue from $186.04M in Q3 2024 to $200.49M in Q2 2025. Gross profit stayed firm with margins at 81% in Q2 2025 versus 77% in Q3 2024. Operating income totaled $48.18M in Q2 2025, maintaining a 24% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $48.18M. Net income dropped to $39.78M, with EPS at $0.69. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan